PE20150869A1 - Tris-(hetero)aril-pirazoles y su uso - Google Patents

Tris-(hetero)aril-pirazoles y su uso

Info

Publication number
PE20150869A1
PE20150869A1 PE2015000171A PE2015000171A PE20150869A1 PE 20150869 A1 PE20150869 A1 PE 20150869A1 PE 2015000171 A PE2015000171 A PE 2015000171A PE 2015000171 A PE2015000171 A PE 2015000171A PE 20150869 A1 PE20150869 A1 PE 20150869A1
Authority
PE
Peru
Prior art keywords
hetero
tris
pirazoles
aril
preparation
Prior art date
Application number
PE2015000171A
Other languages
English (en)
Inventor
Steffen Wildum
Burkhard Klenke
Astrid Wendt
Original Assignee
Aicuris Gmbh And Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48986151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150869(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Gmbh And Co Kg filed Critical Aicuris Gmbh And Co Kg
Publication of PE20150869A1 publication Critical patent/PE20150869A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion se refiere a nuevos tris-(hetero)aril-pirazoles, a procedimientos para su preparacion, a su uso para el tratamiento y/o la profilaxis de enfermedades como tambien a su uso para la preparacion de medicamentos para el tratamiento y/o la profilaxis de enfermedades, en especial de enfermedades retrovirales, en humanos y/o animales
PE2015000171A 2012-08-17 2013-08-16 Tris-(hetero)aril-pirazoles y su uso PE20150869A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102012016908.6A DE102012016908A1 (de) 2012-08-17 2012-08-17 Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung

Publications (1)

Publication Number Publication Date
PE20150869A1 true PE20150869A1 (es) 2015-05-27

Family

ID=48986151

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000171A PE20150869A1 (es) 2012-08-17 2013-08-16 Tris-(hetero)aril-pirazoles y su uso

Country Status (27)

Country Link
US (1) US9249148B2 (es)
EP (1) EP2885300A1 (es)
JP (1) JP2015524835A (es)
KR (1) KR20150042841A (es)
CN (1) CN104684913B (es)
AP (1) AP2015008325A0 (es)
AR (1) AR092145A1 (es)
AU (1) AU2013303993A1 (es)
BR (1) BR112015003115A2 (es)
CA (1) CA2881997A1 (es)
CL (1) CL2015000362A1 (es)
CU (1) CU20150015A7 (es)
DE (1) DE102012016908A1 (es)
EA (1) EA201500232A1 (es)
HK (1) HK1212327A1 (es)
IL (1) IL237298A0 (es)
MA (1) MA37928A1 (es)
MX (1) MX2015002046A (es)
NZ (1) NZ704727A (es)
PE (1) PE20150869A1 (es)
PH (1) PH12015500322A1 (es)
SG (1) SG11201501183VA (es)
TN (1) TN2015000045A1 (es)
TW (1) TW201412720A (es)
UA (1) UA112488C2 (es)
WO (1) WO2014027112A1 (es)
ZA (1) ZA201501078B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
AR099428A1 (es) * 2014-02-14 2016-07-20 Aicuris Gmbh & Co Kg Combinaciones de principios activos farmacéuticos con compuestos basados en tri(hetero)aril pirazoles
EP3263567A1 (en) * 2016-07-01 2018-01-03 AiCuris Anti-infective Cures GmbH Carboxamide-substituted pyrazoles and tri(hetero)aryl-pyrazoles for use in methods of treating and / or preventing cardiovascular diseases and / or comorbidities thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
IL104311A (en) 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6277847B1 (en) 1999-04-02 2001-08-21 Fmc Corporation Herbicidal isoindolinonyl-and 3,4-dihydroisoquinolonyl-substituted heterocycles
WO2003037274A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
US6649638B1 (en) * 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
PL377778A1 (pl) 2002-12-02 2006-02-20 Astellas Pharma Inc. Pochodne pirazolu
EP1591443B1 (en) 2003-02-07 2010-08-25 Daiichi Sankyo Company, Limited Pyrazole derivative
DE602005016082D1 (de) 2004-02-20 2009-10-01 Astrazeneca Ab 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen
ES2314633T3 (es) 2004-03-26 2009-03-16 F. Hoffmann-La Roche Ag Tetrahidrocarbazoles y derivados.
EP1762568A1 (en) 2004-07-01 2007-03-14 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives
GB0417910D0 (en) 2004-08-11 2004-09-15 Novartis Ag Organic compounds
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
BRPI0612287A8 (pt) 2005-06-27 2019-01-22 Exelixis Inc composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
EP1743637A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
WO2007009701A2 (en) 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
GB0516661D0 (en) 2005-08-13 2005-09-21 Astrazeneca Ab Therapeutic agents
CN101263130B (zh) 2005-09-13 2011-03-09 詹森药业有限公司 2-苯胺-4-芳基取代的噻唑衍生物
US20090143413A1 (en) 2005-11-29 2009-06-04 Adams Alan D Thiazole Derivatives as CXCR3 Receptor Modulators
JP2009518298A (ja) 2005-12-01 2009-05-07 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療に有用な尿素化合物
WO2008017932A2 (en) 2006-08-09 2008-02-14 Pfizer Products Inc. Heterocycles useful as inhibitors of carbonic anhydrase
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
GB0625196D0 (en) 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
JP4994295B2 (ja) * 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
JP5258904B2 (ja) 2008-02-18 2013-08-07 エフ．ホフマン−ラ ロシュ アーゲー ４，５−ジヒドロオキサゾール−２−イルアミン誘導体
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008015032A1 (de) * 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
KR101710197B1 (ko) 2009-09-17 2017-02-24 얀센 파마슈티카 엔.브이. 치환된 ｎ-페닐-1-(4-피리디닐)-1ｈ-피라졸-3-아민
EA201290305A1 (ru) 2009-11-13 2012-12-28 Мерк Сероно С.А. Производные трициклического пиразоламина
EP2595986A2 (en) * 2010-07-14 2013-05-29 Addex Pharma SA Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
EP2632461A4 (en) 2010-10-29 2014-04-02 Merck Sharp & Dohme ISOINDOLINONE COMPOUNDS USEFUL AS PDE INHIBITORS 10
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
AR099428A1 (es) 2014-02-14 2016-07-20 Aicuris Gmbh & Co Kg Combinaciones de principios activos farmacéuticos con compuestos basados en tri(hetero)aril pirazoles

Also Published As

Publication number Publication date
BR112015003115A2 (pt) 2017-07-04
US20150203500A1 (en) 2015-07-23
AR092145A1 (es) 2015-03-25
PH12015500322B1 (en) 2015-03-30
KR20150042841A (ko) 2015-04-21
PH12015500322A1 (en) 2015-03-30
JP2015524835A (ja) 2015-08-27
CN104684913B (zh) 2016-11-23
WO2014027112A1 (de) 2014-02-20
AP2015008325A0 (en) 2015-03-31
CA2881997A1 (en) 2014-02-20
CN104684913A (zh) 2015-06-03
IL237298A0 (en) 2015-04-30
DE102012016908A1 (de) 2014-02-20
ZA201501078B (en) 2017-11-29
EA201500232A1 (ru) 2015-07-30
AU2013303993A1 (en) 2015-03-12
NZ704727A (en) 2016-07-29
TW201412720A (zh) 2014-04-01
US9249148B2 (en) 2016-02-02
MX2015002046A (es) 2015-06-05
CL2015000362A1 (es) 2015-07-10
MA37928A1 (fr) 2017-11-30
UA112488C2 (uk) 2016-09-12
CU20150015A7 (es) 2015-11-27
SG11201501183VA (en) 2015-05-28
HK1212327A1 (en) 2016-06-10
EP2885300A1 (de) 2015-06-24
TN2015000045A1 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
ECSP15001882A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
CU20160087A7 (es) Indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen
CR20150370A (es) Compuestos antivirales
UY36966A (es) Derivados de heterociclos bicíclicos fusionados como plaguicidas
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
CR20170478A (es) Compuestos novedosos
ECSP15022555A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
PE20151157A1 (es) Formas de dosificacion de ruxolitinib de liberacion sostenida
PE20151023A1 (es) Triazolopirazinas
HN2010001920A (es) Dihidropirazolonas sustituidas como inhibidores de hif- propil-4-hidroxilasa
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
UY32502A (es) Agentes antihelmínticos y su utilización
NI201500050A (es) Benzamidas
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CO2018010689A2 (es) Derivados de aminotiazol útiles como agentes antivíricos
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
UY35745A (es) Derivados sustituidos de fenilalanina
CO7131397A2 (es) Derivados de n- cicloalquil-n- [(heterociclilfenil)metilen]-(tio) carboxamida

Legal Events

Date Code Title Description
FD Application declared void or lapsed